Eady, N;
Sheehan, R;
Rantell, K;
Sinai, A;
Bernal, J;
Bohnen, I;
Bonell, S;
... Strydom, A; + view all
(2018)
Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study.
British Journal of Psychiatry
, 212
(3)
pp. 155-160.
10.1192/bjp.2017.21.
Preview |
Text
Eady_Impact_cholinesterase_inhibitors.pdf - Accepted Version Download (641kB) | Preview |
Abstract
Background: There is little evidence to guide pharmacological treatment in adults with Down syndrome and Alzheimer's disease. / Aims: To investigate the effect of cholinesterase inhibitors or memantine on survival and function in adults with Down syndrome and Alzheimer's disease. / Method: This was a naturalistic longitudinal follow-up of a clinical cohort of 310 people with Down syndrome diagnosed with Alzheimer's disease collected from specialist community services in England. / Results: Median survival time (5.59 years, 95% CI 4.67–6.67) for those on medication (n = 145, mainly cholinesterase inhibitors) was significantly greater than for those not prescribed medication (n = 165) (3.45 years, 95% CI 2.91–4.13, log-rank test P<0.001). Sequential assessments demonstrated an early effect in maintaining cognitive function. / Conclusions: Cholinesterase inhibitors appear to offer benefit for people with Down syndrome and Alzheimer's disease that is comparable with sporadic Alzheimer's disease; a trial to test the effect of earlier treatment (prodromal Alzheimer's disease) in Down syndrome may be indicated. / Declaration of interest: A.S. has undertaken consulting for Ono Pharmaceuticals, outside the submitted work. Z.W. has received a consultancy fee and grant from GE Healthcare, outside the submitted work.
| Type: | Article |
|---|---|
| Title: | Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1192/bjp.2017.21 |
| Publisher version: | https://doi.org/10.1192/bjp.2017.21 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10040930 |
Archive Staff Only
 |
View Item |
